Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

China

Capital Institute of Pediatrics, Beijing, Beijing Municipality

Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Shanghai Ninth People Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality

West China Hospital of Sichuan University, Chengdu, Sichuan